Mesenchymal Autologous Stem Cells

• Published in: World neurosurgery Vol. 83; no. 2; pp. 236 - 250
• Main Authors: Falavigna, Asdrubal, Costa da Costa, Jaderson
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2015
• Subjects: Animals; Cell transplantation; Cell- and Tissue-Based Therapy - methods; Clinical translations; Humans; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stromal Cells; Neuronal differentiation; Neurosurgery; Spinal Cord Injuries - surgery; Spinal cord injury; LP; Stem cell; Central nervous system; CNS; MHC; BM; Spinal cord injury; SC; Clinical translations; ESC; Bone marrow; MSC; Vascular endothelial growth factor; Cell transplantation; Mesenchymal stem cells; Proteoglycans; BDNF; Intravenous; VEGF; Embryonic stem cells; iPS; IV; Lumbar puncture; CS; Major histocompatibility complex; Brain: derived neurotrophic factor; PG; Neuronal differentiation; SCI; Chondroitin sulfate; Induced pluripotent cells
• ISSN: 1878-8750; 1878-8769
• DOI: 10.1016/j.wneu.2013.02.026

The use of cell-based therapies for spinal cord injuries has recently gained prominence as a potential therapy or component of a combination strategy. Experimental and clinical studies have been performed using mesenchymal stem cell therapy to treat spinal cord injuries with encouraging results. However, there have been reports on the adverse effects of these stem cell–based therapies, especially in the context of tumor modulation. This article surveys the literature relevant to the potential of mesenchymal autologous stem cells for spinal cord injuries and their clinical implications.